ΒιΆΉ΄«Γ½

Meeting Coverage

ASCO Video Pearls: Metastatic Breast Cancer

Video Pearls from the American Society of Clinical Oncology

Highlights in Metastatic Breast Cancer: Key Findings From ASCO 2024

Haten Soliman, MD, talks about advancements in early treatment and CDK4/6 inhibitors

image

Latest ASCO Video Pearls: Metastatic Breast Cancer Meeting Coverage

Study Supports Continued Use of CDK4/6 Inhibitors in Advanced Breast Cancer

Joanne Mortimer, MD, on a phase III trial adding abemaciclib to fulvestrant in the second line

July 3, 2024
TNBC: Distinct Tumor Immune Microenvironments at Metastatic Sites

"Striking differences," says researcher

June 26, 2024
Breast Cancer Highlights From ASCO 2024

Adriana Kahn, MD, highlights some of the exciting research in the metastatic setting

June 18, 2024
Testing PD-1 Inhibition With Neoadjuvant Anti-HER2 Therapy in Breast Cancer

Jin Sun L. Bitar provides an overview of the ongoing neoHIP trial

July 3, 2023
CDK4/6 Inhibitors in Breast Cancer: New Populations, Different Settings

Maryam Lustberg, MD, details three posters she was a discussant on at ASCO 2023

June 26, 2023
T-DXd Benefit in Metastatic Breast Cancer Extends to Older Patients

Those 65 and up had the same efficacy along with an "acceptable" increase in toxicity

June 20, 2023
Adjuvant Ribociclib Cuts Recurrence in Early-Stage Breast Cancer

Including CDK4/6 inhibitor with endocrine therapy improved invasive disease-free survival

June 12, 2023
What to Make of Sacituzumab Govitecan in HR-Positive Breast Cancer

Megan Kruse, MD, says we need to balance the efficacy and toxicity in a real-world setting

July 12, 2022
Combo Promising in Metastatic, ESR1-Mutated Breast Cancer

Lasofoxifene plus abemaciclib elicited encouraging PFS with an acceptable toxicity profile

July 7, 2022
Sacituzumab Govitecan a 'New Option' in HR+ Metastatic Breast Cancer

Jane Meisel, MD, discusses the implications of the TROPiCS-02 study

June 28, 2022
DESTINY-Breast04 'Practice Changing' for HER2-Low Breast Cancer

Trastuzumab deruxtecan shows remarkable improvement in progression-free and overall survival

June 21, 2022
Studies Confirm OS Benefit With CDK4/6 Inhibitors in Advanced Breast Cancer

William Gradishar discusses the PALOMA-3 and MONALEESA-3 trials

July 6, 2021
CDK4/6 Inhibitor Maintained OS Benefit in Advanced Breast Cancer

Sayeh Lavasani discusses the latest updates from MONALEESA-3

June 29, 2021
Targeting Myeloid-Derived Suppressor Cells in Advanced Cancer

A promising strategy for improving responses with checkpoint inhibition

June 22, 2021